enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 922,661 shares, a decrease of 25.3% from the February 26th total of 1,235,753 shares. Currently, 1.5% of the shares of the company are sold short. Based on an average trading volume of 906,038 shares, the short-interest ratio is currently 1.0 days.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently modified their holdings of the company. Affinity Asset Advisors LLC acquired a new position in enGene during the second quarter worth about $280,000. Braidwell LP bought a new stake in shares of enGene in the 3rd quarter worth approximately $15,479,000. ADAR1 Capital Management LLC bought a new position in shares of enGene in the fourth quarter valued at $2,742,000. Kennedy Capital Management LLC bought a new position in shares of enGene in the fourth quarter valued at $693,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of enGene during the 4th quarter valued at $439,000. Institutional investors own 64.16% of the company’s stock.

enGene Stock Performance

Shares of ENGN opened at $6.18 on Tuesday. The firm has a market capitalization of $414.00 million, a PE ratio of -2.75 and a beta of -0.29. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $9.00 and a 200 day moving average price of $8.31. enGene has a 52-week low of $2.65 and a 52-week high of $12.25.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. On average, sell-side analysts anticipate that enGene will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Jefferies Financial Group started coverage on shares of enGene in a research note on Friday, January 30th. They set a “buy” rating and a $28.00 target price for the company. Raymond James Financial restated a “strong-buy” rating and issued a $27.00 price target on shares of enGene in a research note on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Monday, March 9th. Citigroup reissued a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Finally, Wall Street Zen upgraded enGene from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.86.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.